Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty
Christopher Wanderling(University of Rochester), Jawed Fareed(Loyola University Medical Center), Elissa Finkler(Loyola University Medical Center), Nil Güler(Loyola University Medical Center), William Hopkinson(Loyola University Medical Center), Debra Hoppensteadt(Loyola University Medical Center), Peter Carlsgaard(Loyola University Chicago), Jeffrey Liles(Loyola University Chicago)
Cited by 19
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Nailfold Capillary Abnormalities in Primary Open-Angle Glaucoma: A Multisite Study
|Investigative Ophthalmology & Visual Science|2015|38
Recent Advances in Surgical Simulation For Resident Education
|Current Urology Reports|2023|30
Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy
|Clinical and Applied Thrombosis/Hemostasis|2016|19
Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients
|Clinical and Applied Thrombosis/Hemostasis|2015|13